Viewing StudyNCT03707847



Ignite Creation Date: 2024-05-06 @ 12:12 PM
Last Modification Date: 2024-10-26 @ 12:56 PM
Study NCT ID: NCT03707847
Status: UNKNOWN
Last Update Posted: 2018-10-16
First Post: 2018-09-23

Brief Title: Crizotinib Combined With Etoposide Capsule Followed by Auto-HSCT for Relapsed and Refractory ALK ALCL
Sponsor: Mingzhi Zhang
Organization: Zhengzhou University

Conditions & Keywords Data

Conditions:
Name
ALK-Positive Anaplastic Large Cell Lymphoma
Keywords:
Name View
adverse events View
crizotinib View
etoposide View
autologous hematopoietic stem cell transplantation View
ORR View
OS View
PFS View